FDA advisory committee
Appears in 2 stories
Voted 6-3 against camizestrant in April 2026; FDA overruled
The Food and Drug Administration approved AstraZeneca's pill Etcamah (camizestrant) on September 4, 2026, for people with metastatic breast cancer whose tumors carry an estrogen receptor-1 (ESR1) mutation. It is the first cancer therapy approved based on a resistance mutation found in blood before scans show the disease has progressed.
Updated 3 days ago
Reviewed camizestrant and Truqap applications on April 30, 2026
For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.
Updated May 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
